肽基甘氨酸α-酰胺化单加氧酶缺陷导致肌少症性糖尿病
研究利用Malmö饮食与癌症研究、Malmö预防项目及英国生物样本库的遗传与表型数据,发现PAM基因两个功能丧失变异独立降低PAM酰胺化活性,累积效应与糖尿病、胰岛素分泌减少、GH和IGF-1升高相关,并导致肌肉质量与功能下降及肌少症风险增加。
要点
- PAM基因Ser539Trp和Asp563Gly变异独立降低PAM酰胺化活性。
- 变异累积效应与糖尿病、胰岛素分泌减少及GH/IGF-1升高相关。
- 携带者肌肉质量与功能下降,肌少症风险增加。
核心结论
- PAM酰胺化活性遗传缺陷导致糖尿病前期肌少症表型。
- 早期识别PAM功能丧失变异携带者有助于针对性运动干预,并需要恢复酶活性的新疗法。
研究设计与样本
- 利用队列研究遗传与表型数据:Malmö饮食与癌症研究(MDC;1991-1996;2002-2012复查)、Malmö预防项目(MPP;2002-2006)和英国生物样本库(UKB;2012)。
- 采用全外显子组关联分析识别与PAM酰胺化活性降低相关的功能丧失变异,再与结局进行关联分析。
- 纳入MDC心血管亚队列约4500名参与者、MPP约4500名参与者和UKB约300000名参与者。
主要发现
- PAM基因Ser539Trp(次要等位基因频率0.7%)和Asp563Gly(5%)两个功能丧失变异分别独立导致PAM酰胺化活性降低2.33个标准差(95%CI:2.52/2.15;P=2.5E-140)和0.98个标准差(95%CI:1.04/0.92;P=1.12E-225)。
- 功能丧失变异的累积效应与糖尿病、胰岛素分泌减少以及GH和IGF-1水平升高相关。
- 携带者肌肉质量和功能下降,随后肌少症风险升高。
- Ser539Trp变异使肌少症风险增加30%(比值比1.31;95%CI:1.16/1.47;P=9.8E-06),独立于年龄和糖尿病。
临床怎么用
- 早期识别PAM功能丧失变异携带者有助于针对性运动干预,并需要恢复酶活性的新疗法。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Peptidylglycine-α-amidating monooxygenase (PAM) is a critical enzyme in the endocrine system responsible for activation, by amidation, of bioactive peptides. OBJECTIVE: To define the clinical phenotype of carriers of genetic mutations associated with impaired PAM-amidating activity (PAM-AMA). DESIGN: We used genetic and phenotypic data from cohort studies: the Malmö Diet and Cancer (MDC; 1991-1996; reexamination in 2002-2012), the Malmö Preventive Project (MPP; 2002-2006), and the UK Biobank (UKB; 2012). SETTING: Exome-wide association analysis was used to identify loss-of-function (LoF) variants associated with reduced PAM-AMA and subsequently used for association with the outcomes. PATIENTS OR OTHER PARTICIPANTS: This study included n∼4500 participants from a subcohort of the MDC (MDC-Cardiovascular cohort), n∼4500 from MPP, and n∼300,000 from UKB. MAIN OUTCOME MEASURES: Endocrine-metabolic traits suggested by prior literature, muscle mass, muscle function, and sarcopenia. RESULTS: Two LoF variants in the PAM gene, Ser539Trp (minor allele frequency: 0.7%) and Asp563Gly (5%), independently contributed to a decrease of 2.33 [95% confidence interval (CI): 2.52/2.15; P = 2.5E-140] and 0.98 (1.04/0.92; P = 1.12E-225) SD units of PAM-AMA, respectively. The cumulative effect of the LoF was associated with diabetes, reduced insulin secretion, and higher levels of GH and IGF-1. Moreover, carriers had reduced muscle mass and function, followed by a higher risk of sarcopenia. Indeed, the Ser539Trp mutation increased the risk of sarcopenia by 30% (odds ratio 1.31; 95% CI: 1.16/1.47; P = 9.8E-06), independently of age and diabetes. CONCLUSION: PAM-AMA genetic deficiency results in a prediabetic sarcopenic phenotype. Early identification of PAM LoF carriers would allow targeted exercise interventions and calls for novel therapies that restore enzymatic activity.
引用
- Giontella A, Åkerlund M, Bronton K, et al. Deficiency of Peptidylglycine-alpha-amidating Monooxygenase, a Cause of Sarcopenic Diabetes Mellitus. J Clin Endocrinol Metab. 2025. PMID: 39137152. doi:10.1210/clinem/dgae510
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。